A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT ID: NCT05519085

This clinical trial is investigating a new treatment combination for patients with relapsed or refractory multiple myeloma (RRMM), which means their cancer has returned or did not respond to previo...

Recruiting

Phase: PHASE3 Conditions: Relapsed or Refractory Multiple Myeloma

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT ID: NCT06292013

The ACCLAIM-Lp(a) trial is studying a new treatment called lepodisiran to see if it can help reduce the risk of serious heart problems in adults who have high levels of a substance called lipoprote...

Recruiting

Phase: PHASE3 Conditions: Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT ID: NCT06890598

This clinical trial is studying a new treatment called olomorasib, which is being tested alongside standard treatments for patients with a specific type of lung cancer known as KRAS G12C-mutant non...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT ID: NCT03486873

This clinical trial, called MK-3475-587, is looking into the long-term safety and effectiveness of a treatment called pembrolizumab (also known as MK-3475) for patients with advanced tumors. If you...

Recruiting

Phase: PHASE3 Conditions: Solid Tumors, Hematologic Malignancies

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT ID: NCT06119581

This clinical trial is investigating whether a new drug called LY3537982, combined with standard cancer treatments like immunotherapy and chemotherapy, is more effective for patients with advanced ...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT ID: NCT06456346

This clinical trial, called MK-3543-007, is studying a new medication called bomedemstat to see if it works better than hydroxyurea for treating people with a condition called Essential Thrombocyth...

Recruiting

Phase: PHASE3 Conditions: Essential Thrombocythemia

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT ID: NCT03519945

The LUCENT 3 clinical trial is studying a medication called mirikizumab to see how effective and safe it is for treating people with moderately to severely active ulcerative colitis (UC) over a lon...

Recruiting

Phase: PHASE3 Conditions: Ulcerative Colitis

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT ID: NCT06383390

The TRIUMPH-OUTCOMES study is looking at a new treatment called retatrutide, which is given once a week, to see if it can help reduce serious heart problems and protect kidney function in adults wh...

Recruiting

Phase: PHASE3 Conditions: Chronic Kidney Disease (CKD), Atherosclerotic Cardiovascular Disease (ASCVD)

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT ID: NCT06052059

This clinical trial is studying a new medication called tulisokibart (MK-7240) to see if it is effective and safe for people with moderately to severely active ulcerative colitis, a condition that ...

Recruiting

Phase: PHASE3 Conditions: Ulcerative Colitis

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT ID: NCT06077760

This clinical trial is looking at a new treatment combination for patients with non-small cell lung cancer (NSCLC) who have had surgery to remove their cancer. The study compares the effects of a d...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT ID: NCT06430801

This clinical trial is studying a new medication called tulisokibart, which is being tested for its effectiveness and safety in treating people with moderate to severe Crohn's disease. Crohn's dise...

Recruiting

Phase: PHASE3 Conditions: Crohn's Disease

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

NCT ID: NCT06465186

This clinical trial is studying a new medicine called efinopegdutide to see if it can help people with a liver disease known as metabolic dysfunction-associated steatohepatitis (MASH), which is cau...

Recruiting

Phase: PHASE2 Conditions: NAFLD, Non-alcoholic Fatty Liver Disease +3 more

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

NCT ID: NCT06161116

This clinical trial is studying a new treatment called MK-6194 for adults with Systemic Lupus Erythematosus (SLE), a condition where the immune system mistakenly attacks healthy tissues. The main g...

Recruiting

Phase: PHASE2 Conditions: Systemic Lupus Erythematosus

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT ID: NCT03888105

This clinical trial is studying a new treatment called odronextamab for adults with B-cell non-Hodgkin lymphoma (B-NHL) who have already tried other cancer therapies. The main goal is to see how ef...

Recruiting

Phase: PHASE2 Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT ID: NCT06356129

This clinical trial is studying a new treatment for patients with a type of cancer called high-risk large B-cell lymphoma (LBCL). Researchers want to see if adding a medication called golcadomide t...

Recruiting

Phase: PHASE3 Conditions: Large B-cell Lymphoma

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

NCT ID: NCT03394365

This clinical trial is studying a new treatment called tabelecleucel for patients who have developed a condition known as Epstein-Barr virus-associated post-transplant lymphoproliferative disease (...

Recruiting

Phase: PHASE3 Conditions: Stem Cell Transplant Complications, Lymphoproliferative Disorders +3 more

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT ID: NCT07063745

This clinical trial is studying a new treatment approach for people with a specific type of advanced lung cancer called metastatic non-small cell lung cancer (NSCLC) who have a particular genetic c...

Not yet recruiting

Phase: PHASE2 Conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT ID: NCT05020236

The MagnetisMM-5 clinical trial is studying a new treatment option for people with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers want to see if a medication called el...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT ID: NCT06152575

The MagnetisMM-32 clinical trial is studying a new medicine called elranatamab for people with multiple myeloma (MM), a type of blood cancer that has returned after previous treatments. The trial a...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

NCT ID: NCT06911502

The GOLSEEK-4 trial is a clinical study designed to compare the effectiveness and safety of a new treatment called golcadomide combined with rituximab against the current best treatment options for...

Not yet recruiting

Phase: PHASE3 Conditions: Follicular Lymphoma

Main Menu

Clinical Trials in Pessac, Aquitaine

27 Active Trials Found in Pessac

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)